伊立替康联合卡培他滨和贝伐珠单抗治疗结直肠癌伴肝转移患者的疗效

doi:10.3969/j.issn.1671-7171.2026.03.020

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1249 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the efficacy of irinotecan combined with capecitabine and bevacizumab in patients with colorectal cancer and liver metastases. 【Methods】 A total of 100 patients with colorectal cancer and liver metastases were randomly divided into an observation group and a control group, with 50 cases in each group. The observation group received irinotecan + capecitabine + bevacizumab, while the control group received oxaliplatin + capecitabine + bevacizumab. Clinical efficacy, serum vascular endothelial growth factor (VEGF) and carbohydrate antigen 19-9 (CA19-9) levels before and after treatment, as well as the incidence of adverse reactions were compared between the two groups. 【Results】 There were no statistically significant differences between the two groups in overall response rate or disease control rate (P>0.05). After treatment, VEGF and CA19-9 levels in the observation group were lower than those in the control group (P<0.05). During an 18-month follow-up, the progression-free survival (PFS) was 9.2 months and 8.1 months, and the median overall survival (OS) was 20.5 months and 19.1 months in the observation and control groups, respectively; no statistically significant differences were found between the two groups (P>0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 Irinotecan + capecitabine + bevacizumab shows similar efficacy and good safety compared with oxaliplatin + capecitabine + bevacizumab in patients with colorectal cancer and liver metastases; however, the observation group demonstrated greater improvements in serum VEGF and CA19-9 levels.

Key words： Colorectal Neoplasms Liver Neoplasms Neoplasm Metastasis Irinotecan Capecitabine Antibodies, Monoclonal

Received: 08 October 2025

PACS:

R735.7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Jing

Cite this article:

ZHU Jing. Efficacy of Irinotecan Combined with Capecitabine and Bevacizumab in Patients with Colorectal Cancer and Liver Metastases[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(3): 425-427.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.03.020 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I3/425

[1] 汪哲,李娜. 维生素D在结直肠癌中的研究进展[J].医学研究与战创伤救治,2023,36(4):425-429.
[2] 黄忠晶,伍子奕,艾军华. 肝移植治疗结直肠癌肝转移的研究进展[J].器官移植,2024,15(2):185-190.
[3] 王韡,程晋坤,杨政道. 伊立替康联合卡培他滨和贝伐珠单抗治疗结直肠癌伴肝转移患者的临床研究[J].中国临床药理学杂志,2024,40(18):2660-2664.
[4] 张庄宜,段丽萍. 伊立替康相关迟发性腹泻:肠道菌群视角[J].中华内科杂志,2024,63(5):507-511.
[5] 武鸿彪,刘东方,刘烨磊. 贝伐珠单抗联合卡培他滨治疗晚期结肠癌的效果[J].中国药物应用与监测,2024,21(3):208-211.
[6] 白玉梅,王海晓,孟东梅,等. 贝伐珠单抗联合卡培他滨维持对晚期结肠癌患者的疗效[J].西北药学杂志,2024,39(6):159-164.
[7] 中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2020年版)[J].中华外科杂志,2020,58(8):561-585.
[8] EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009, 45(2): 228-247.
[9] SINICROPE F A. Increasing incidence of early-onset colorectal cancer[J].N Engl J Med,2022, 386(16): 1547-1558.
[10] SHIN A E, GIANCOTTI F G, RUSTGI A K. Metastatic colorectal cancer: mechanisms and emerging therapeutics[J].Trends Pharmacol Sci,2023, 44(4): 222-236.
[11] 杨烈,郭思琪. 结直肠癌伴同时性肝转移外科治疗的策略与实践[J].中华消化外科杂志,2025,24(6):726-732.
[12] AYKUT B, LIDSKY M E. Colorectal cancer liver metastases: multimodal therapy[J].Surg Oncol Clin N Am,2023, 32(1): 119-141.
[13] 王大强,鞠后琼,仲崇晗,等. 结直肠癌伴同时性不可切除肝转移转化治疗的疗效分析[J].中华普通外科杂志,2023,38(6):407-411.
[14] MAHAKI H, MANSOURIAN M, MESHKAT Z, et al. Nanoparticles containing oxaliplatin and the treatment of colorectal cancer[J].Curr Pharm Des,2023, 29(38): 3018-3039.
[15] 陈梦园,范小斌,陈晓天. 奥沙利铂、伊立替康辅助治疗结直肠癌伴肝转移的治疗效果[J].青岛医药卫生,2025,57(4):291.